Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Nuvalent, Inc.NASDAQ: NUVL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
NUVL Competitors
Gross Profit for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$3.03B USD-14.7%+6.5%64.2%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$724.04M USD+59.9%+136.2%93.2%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$449.02M USD-45.9%+25.3%99.6%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$247.69M USD+58.9%+99.3%88.2%
CYTKCytokinetics, IncorporatedLTM Jun 2026$62.98M USD-26.5%—88.7%
NUVLNuvalent, Inc.LTM Mar 2026$0 USD———
ABVXAbivax S.A.FY2025€0 EUR———
PCVXVaxcyte, Inc.LTM Jun 2026-$865K USD+82.7%——
CRSPCRISPR Therapeutics AGLTM Sep 2026-$140.69M USD-4.7%—558.9%
Peer median (excluding NUVL) —-4.7%+62.3%91.0%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.